Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis

Company Overview

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination. The management team brings together professionals with backgrounds in healthcare, life sciences and investment banking, aiming to leverage their combined expertise to target companies that address supply‐chain resilience and onshore production of critical prescription medications. The company is headquartered in New York and serves as a vehicle for investors seeking exposure to the U.S. pharmaceutical manufacturing industry.

Since its initial public offering on the Nasdaq Stock Market, Drugs Made In America Acquisition has been evaluating potential transaction candidates across the United States and is working toward identifying a suitable partner that aligns with its goal of bolstering domestic drug production capabilities. Pending the closing of a qualifying business combination, the SPAC will continue to operate under regulatory guidelines governing blank‐check companies and pursue opportunities intended to create long‐term shareholder value through a combination that reinforces American pharmaceutical independence.

Key Stats

• Today's Range: $10.56 to $10.60
• 50-Day Range: $10.46 to $10.58
• 52-Week Range: $10.07 to $10.60
• Volume: 1,666 shs
• Average Volume: 265,445 shs
• Market Capitalization: $356.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

DMAA Stock Analysis - Frequently Asked Questions

How have DMAA shares performed this year?

Drugs Made In America Acquisition's stock was trading at $10.3742 at the beginning of the year. Since then, DMAA stock has increased by 2.0% and is now trading at $10.58.

How do I buy shares of Drugs Made In America Acquisition?

Shares of DMAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Financial Services
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:DMAA
• CIK: 2028614
• Web: N/A
• Phone: (954) 870-3104
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,720,000
• Free Float: 33,414,000
• Market Cap: $356.76 million
• Optionable: N/A
• Beta: 0.01